{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:00:16Z","timestamp":1794096016523,"version":"4.8.0"},"reference-count":155,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists are increasingly recognized for their potential dual benefit in inflammatory bowel disease (IBD), offering metabolic advantages alongside emerging anti-inflammatory, immunomodulatory, and gut barrier-enhancing effects. Pre-clinical data demonstrate attenuation of inflammation, preservation of epithelial integrity, and modulation of the microbiome in colitis models. Early retrospective studies in patients with IBD suggest improved clinical outcomes, such as reduced hospitalization and surgery rates, particularly in those with obesity. Glucagon-like peptide-1 receptor agonists are already widely used for obesity and diabetes, including increasing self-administration by patients outside medical supervision. Their impact on drug absorption, safety in gastrointestinal disease, and interactions with existing IBD therapies require further exploration. This review synthesizes the mechanistic rationale, pre-clinical evidence, and clinical data to date, highlighting the potential utility and safety considerations of glucagon-like peptide-1 receptor agonists in IBD and emphasizes the need for robust prospective trials to ascertain their safety and efficacy in this patient population.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaf167","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:39:42Z","timestamp":1757763582000},"source":"Crossref","is-referenced-by-count":30,"title":["Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-8358","authenticated-orcid":false,"given":"Michael","family":"Colwill","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust , London,","place":["United Kingdom"]},{"name":"Institute for Infection and Immunity, City St George\u2019s University Medical School , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Povlsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pollok","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, City St George\u2019s University Medical School , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Goodhand","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital , Exeter,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-5528","authenticated-orcid":false,"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Devon and Exeter Hospital , Exeter,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-2763","authenticated-orcid":false,"given":"Sailish","family":"Honap","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust , London,","place":["United Kingdom"]},{"name":"School of Immunology and Microbial Sciences, King\u2019s College London , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2025102819145573800_jjaf167-B1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"2025102819145573800_jjaf167-B2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"The Lancet"},{"key":"2025102819145573800_jjaf167-B3"},{"key":"2025102819145573800_jjaf167-B4","first-page":"178","article-title":"Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes","volume":"10","author":"Tran","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"2025102819145573800_jjaf167-B5","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.2337\/dci25-0023","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"2025102819145573800_jjaf167-B6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102819145573800_jjaf167-B7","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"2025102819145573800_jjaf167-B8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/imm.13784","article-title":"GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells","volume":"172","author":"Sun","year":"2024","journal-title":"Immunology"},{"key":"2025102819145573800_jjaf167-B9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1097\/MIB.0000000000000847","article-title":"GLP-1 induces barrier protective expression in Brunner\u2019s glands and regulates colonic inflammation","volume":"22","author":"Bang-Berthelsen","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819145573800_jjaf167-B10","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"2025102819145573800_jjaf167-B11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","article-title":"Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes","volume":"14","author":"Singh","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025102819145573800_jjaf167-B12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/ibd\/izy278","article-title":"Visceral adipose tissue is associated with stricturing Crohn\u2019s disease behavior, fecal calprotectin, and quality of life","volume":"25","author":"Bryant","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819145573800_jjaf167-B13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/DCR.0000000000001085","article-title":"The obese colorectal surgery patient: surgical site infection and outcomes","volume":"61","author":"Wahl","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"2025102819145573800_jjaf167-B14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.14309\/ajg.0000000000000197","article-title":"Impact of obesity on disease activity and patient-reported outcomes measurement information system (PROMIS) in inflammatory bowel diseases","volume":"114","author":"Jain","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025102819145573800_jjaf167-B15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","article-title":"Effects of obesity on pharmacokinetics","volume":"39","author":"Cheymol","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"2025102819145573800_jjaf167-B16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40259-022-00522-0","article-title":"Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases","volume":"36","author":"Bassi","year":"2022","journal-title":"BioDrugs"},{"key":"2025102819145573800_jjaf167-B17","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819145573800_jjaf167-B18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"2025102819145573800_jjaf167-B19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.79.2.345","article-title":"Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem","volume":"79","author":"Lund","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025102819145573800_jjaf167-B20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"2025102819145573800_jjaf167-B21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster preproglucagon contains the sequence of glucagon and two related peptides","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"2025102819145573800_jjaf167-B22","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1073\/pnas.80.18.5485","article-title":"Mammalian pancreatic preproglucagon contains three glucagon-related peptides","volume":"80","author":"Lopez","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025102819145573800_jjaf167-B23","doi-asserted-by":"crossref","first-page":"11880","DOI":"10.1016\/S0021-9258(18)67324-7","article-title":"Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing","volume":"261","author":"Mojsov","year":"1986","journal-title":"J Biol Chem"},{"key":"2025102819145573800_jjaf167-B24","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025102819145573800_jjaf167-B25","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025102819145573800_jjaf167-B26","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J Clin Invest"},{"key":"2025102819145573800_jjaf167-B27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2025102819145573800_jjaf167-B28","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"2025102819145573800_jjaf167-B29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MED.0b013e32833463ed","article-title":"Somatostatin and the gastrointestinal tract","volume":"17","author":"Corleto","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2025102819145573800_jjaf167-B30","doi-asserted-by":"crossref","first-page":"e00815","DOI":"10.14309\/ctg.0000000000000815","article-title":"Treatment of bile acid diarrhea with glucagon-like peptide 1 receptor agonists: a promising yet understudied approach","volume":"16","author":"Ellegaard","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"key":"2025102819145573800_jjaf167-B31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bph.15611","article-title":"Actions of glucagon-like peptide-1 receptor ligands in the gut","volume":"179","author":"Holst","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2025102819145573800_jjaf167-B32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"2025102819145573800_jjaf167-B33","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1113\/jphysiol.2009.175067","article-title":"Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions","volume":"587","author":"Holmes","year":"2009","journal-title":"J Physiol"},{"key":"2025102819145573800_jjaf167-B34","first-page":"G984","article-title":"Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow","volume":"275","author":"Wettergren","year":"1998","journal-title":"Am J Physiol"},{"key":"2025102819145573800_jjaf167-B35","doi-asserted-by":"crossref","first-page":"G1117","DOI":"10.1152\/ajpgi.00035.2013","article-title":"The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty","volume":"304","author":"Plamboeck","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025102819145573800_jjaf167-B36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: implications for food and drug reward","volume":"7","author":"Skibicka","year":"2013","journal-title":"Front Neurosci"},{"key":"2025102819145573800_jjaf167-B37","doi-asserted-by":"crossref","first-page":"R200","DOI":"10.1530\/EC-21-0130","article-title":"How glucagon-like peptide 1 receptor agonists work","volume":"10","author":"Andreasen","year":"2021","journal-title":"Endocr Connect"},{"key":"2025102819145573800_jjaf167-B38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"2025102819145573800_jjaf167-B39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2013a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025102819145573800_jjaf167-B40","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"2025102819145573800_jjaf167-B41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"2025102819145573800_jjaf167-B42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(23)01201-1","article-title":"Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists","volume":"402","author":"Nauck","year":"2023","journal-title":"Lancet"},{"key":"2025102819145573800_jjaf167-B43","doi-asserted-by":"crossref","first-page":"e2314493","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025102819145573800_jjaf167-B44","doi-asserted-by":"crossref","first-page":"767-P","DOI":"10.2337\/db24-767-P","article-title":"767-P: a phase 1b\/2a study of the safety and tolerability of GSBR-1290, a novel oral small molecule glucagon-like peptide 1 receptor agonist (GLP-1RA), in healthy overweight\/obese volunteers (HOV) and participants with type 2 diabetes mellitus (T2DM)","volume":"73","author":"Coll","year":"2024","journal-title":"Diabetes"},{"key":"2025102819145573800_jjaf167-B45"},{"key":"2025102819145573800_jjaf167-B46","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025102819145573800_jjaf167-B47","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2025102819145573800_jjaf167-B48","author":"Samaranayake","year":"2022"},{"key":"2025102819145573800_jjaf167-B49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/COPD.S393323","article-title":"The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease","volume":"18","author":"Wang","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025102819145573800_jjaf167-B50","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.2513","article-title":"Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells","volume":"17","author":"Ellingsgaard","year":"2011","journal-title":"Nat Med"},{"key":"2025102819145573800_jjaf167-B51","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/db13-0903","article-title":"Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway","volume":"63","author":"Nguyen","year":"2014","journal-title":"Diabetes"},{"key":"2025102819145573800_jjaf167-B52","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule","volume":"36","author":"Ben Nasr","year":"2024","journal-title":"Cell Metab"},{"key":"2025102819145573800_jjaf167-B53","doi-asserted-by":"crossref","first-page":"8843310","DOI":"10.1155\/2020\/8843310","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide ameliorates the development of periodontitis","volume":"2020","author":"Sawada","year":"2020","journal-title":"J Diabetes Res"},{"key":"2025102819145573800_jjaf167-B54","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1159\/000485776","article-title":"Exendin-4 induces bone marrow stromal cells migration through bone marrow-derived macrophages polarization via PKA-STAT3 signaling pathway","volume":"44","author":"Wang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"2025102819145573800_jjaf167-B55","first-page":"3573","article-title":"Glucagon\u2011like peptide\u20111 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway","volume":"17","author":"Wan","year":"2019","journal-title":"Exp Ther Med"},{"key":"2025102819145573800_jjaf167-B56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"2025102819145573800_jjaf167-B57","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.18632\/aging.204953","article-title":"The alleviating effect and mechanism of GLP-1 on ulcerative colitis","volume":"15","author":"Wang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2025102819145573800_jjaf167-B58","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"2025102819145573800_jjaf167-B59","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2025102819145573800_jjaf167-B60","doi-asserted-by":"crossref","first-page":"300060521992981","DOI":"10.1177\/0300060521992981","article-title":"GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-\u03baB signalling pathway","volume":"49","author":"Chen","year":"2021","journal-title":"J Int Med Res"},{"key":"2025102819145573800_jjaf167-B61","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3748\/wjg.v22.i7.2195","article-title":"Role of regulatory T cell in the pathogenesis of inflammatory bowel disease","volume":"22","author":"Yamada","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2025102819145573800_jjaf167-B62","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","article-title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","volume":"34","author":"Wong","year":"2022","journal-title":"Cell Metab"},{"key":"2025102819145573800_jjaf167-B63","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"2025102819145573800_jjaf167-B64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41590-018-0304-y","article-title":"\u03b3\u03b4 TCR ligands: the quest to solve a 500-million-year-old mystery","volume":"20","author":"Willcox","year":"2019","journal-title":"Nat Immunol"},{"key":"2025102819145573800_jjaf167-B65","doi-asserted-by":"crossref","first-page":"1206299","DOI":"10.3389\/fimmu.2023.1206299","article-title":"The intestinal \u03b3\u03b4 T cells: functions in the gut and in the distant organs","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"2025102819145573800_jjaf167-B66","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1073\/pnas.212290499","article-title":"Protection of the intestinal mucosa by intraepithelial gamma delta T cells","volume":"99","author":"Chen","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025102819145573800_jjaf167-B67","doi-asserted-by":"crossref","first-page":"eadh0301","DOI":"10.1126\/science.adh0301","article-title":"Conserved \u03b3\u03b4 T cell selection by BTNL proteins limits progression of human inflammatory bowel disease","volume":"381","author":"Dart","year":"2023","journal-title":"Science"},{"key":"2025102819145573800_jjaf167-B68","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3390\/cells11071187","article-title":"GLP-1 mediates regulation of colonic ACE2 expression by the bile acid receptor GPBAR1 in inflammation","volume":"11","author":"Biagioli","year":"2022","journal-title":"Cells"},{"key":"2025102819145573800_jjaf167-B69","doi-asserted-by":"crossref","first-page":"13533","DOI":"10.1038\/s41598-021-92979-2","article-title":"Increased colonic expression of ACE2 associates with poor prognosis in Crohn\u2019s disease","volume":"11","author":"Toyonaga","year":"2021","journal-title":"Sci Rep"},{"key":"2025102819145573800_jjaf167-B70","doi-asserted-by":"crossref","first-page":"628157","DOI":"10.1155\/2015\/628157","article-title":"Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut","volume":"2015","author":"Michielan","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2025102819145573800_jjaf167-B71","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.celrep.2017.10.008","article-title":"Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion","volume":"21","author":"Lebrun","year":"2017","journal-title":"Cell Rep"},{"key":"2025102819145573800_jjaf167-B72","first-page":"bqab216","article-title":"Expression profile of the GLP-1 receptor in the gastrointestinal tract and pancreas in adult female mice","volume":"163","author":"Grunddal","year":"2022","journal-title":"Endocrinology"},{"key":"2025102819145573800_jjaf167-B73","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2025102819145573800_jjaf167-B74","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1073\/pnas.0912678107","article-title":"Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1\/Th2 driven enteritis","volume":"107","author":"Pastorelli","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025102819145573800_jjaf167-B75","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/ibd.22900","article-title":"IL-33 attenuates development and perpetuation of chronic intestinal inflammation","volume":"18","author":"Gro\u03b2","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819145573800_jjaf167-B76","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/eji.200324347","article-title":"CCR6 has a non-redundant role in the development of inflammatory bowel disease","volume":"33","author":"Varona","year":"2003","journal-title":"Eur J Immunol"},{"key":"2025102819145573800_jjaf167-B77","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1023\/B:JOCI.0000018066.46279.6b","article-title":"Increased expression of CCL20 in human inflammatory bowel disease","volume":"24","author":"Kaser","year":"2004","journal-title":"J Clin Immunol"},{"key":"2025102819145573800_jjaf167-B78","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jgh.13808","article-title":"Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats","volume":"33","author":"Nozu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2025102819145573800_jjaf167-B79","doi-asserted-by":"crossref","first-page":"G288","DOI":"10.1152\/ajpgi.00453.2006","article-title":"Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats","volume":"293","author":"Simonsen","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025102819145573800_jjaf167-B80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cmet.2015.02.005","article-title":"GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7","volume":"21","author":"Koehler","year":"2015","journal-title":"Cell Metab"},{"key":"2025102819145573800_jjaf167-B81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ibd\/izac194","article-title":"Searching for a consensus among inflammatory bowel disease studies: a systematic meta-analysis","volume":"29","author":"Abdel-Rahman","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819145573800_jjaf167-B82","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.immuni.2018.12.015","article-title":"Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and ROR\u03b3t+ regulatory T cells and exacerbate colitis in mice","volume":"50","author":"Britton","year":"2019","journal-title":"Immunity"},{"key":"2025102819145573800_jjaf167-B83","doi-asserted-by":"crossref","first-page":"883495","DOI":"10.3389\/fmicb.2022.883495","article-title":"The distinguishing bacterial features from active and remission stages of ulcerative colitis revealed by paired fecal metagenomes","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Microbiol"},{"key":"2025102819145573800_jjaf167-B84","doi-asserted-by":"crossref","first-page":"101924","DOI":"10.1016\/j.molmet.2024.101924","article-title":"GLP-1R signaling modulates colonic energy metabolism, goblet cell number and survival in the absence of gut microbiota","volume":"83","author":"Greiner","year":"2024","journal-title":"Mol Metab"},{"key":"2025102819145573800_jjaf167-B85","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/gutjnl-2020-323877","article-title":"Blue poo: impact of gut transit time on the gut microbiome using a novel marker","volume":"70","author":"Asnicar","year":"2021","journal-title":"Gut"},{"key":"2025102819145573800_jjaf167-B86","doi-asserted-by":"crossref","first-page":"1134105","DOI":"10.3389\/fmicb.2023.1134105","article-title":"The analysis of gut microbiota in patients with bile acid diarrhoea treated with colesevelam","volume":"14","author":"Kumar","year":"2023","journal-title":"Front Microbiol"},{"key":"2025102819145573800_jjaf167-B87","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.obpill.2024.100121","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes Pillars"},{"key":"2025102819145573800_jjaf167-B88","doi-asserted-by":"crossref","first-page":"e174825","DOI":"10.1172\/jci.insight.174825","article-title":"Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice","volume":"10","author":"Hammoud","year":"2024","journal-title":"JCI Insight"},{"key":"2025102819145573800_jjaf167-B89","doi-asserted-by":"crossref","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025102819145573800_jjaf167-B90","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.3390\/biomedicines11123256","article-title":"The impact of obesity on inflammatory bowel disease","volume":"11","author":"Kaazan","year":"2023","journal-title":"Biomedicines"},{"key":"2025102819145573800_jjaf167-B91","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.dld.2022.08.017","article-title":"Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis","volume":"55","author":"Fuschillo","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2025102819145573800_jjaf167-B92","doi-asserted-by":"crossref","first-page":"jjae160","DOI":"10.1093\/ecco-jcc\/jjae160","article-title":"GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the Epi-IIRN","volume":"55","author":"Gorelik","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025102819145573800_jjaf167-B93","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819145573800_jjaf167-B94","doi-asserted-by":"crossref","first-page":"S-1518","DOI":"10.1016\/S0016-5085(25)04370-7","article-title":"Tu1841: evaluating the outcomes of Glp-1 receptor agonist use in inflammatory bowel disease (IBD): a systematic review and meta-analysis","volume":"169","author":"Jaber","year":"2025","journal-title":"Gastroenterology"},{"key":"2025102819145573800_jjaf167-B95","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/ibd\/izae250","article-title":"GLP-1 receptor agonists confer no increased rates of IBD exacerbation among patients with IBD","volume":"31","author":"Levine","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819145573800_jjaf167-B96","doi-asserted-by":"crossref","first-page":"S-1220","DOI":"10.1016\/S0016-5085(25)03695-9","article-title":"Mo1908: glucagon-like peptide-1 receptor agonist use in patients with perianal fistulizing Crohn\u2019s disease is well tolerated and leads to weight loss and clinical improvement in fistula activity","volume":"169","author":"Bergenholtz","year":"2025","journal-title":"Gastroenterology"},{"key":"2025102819145573800_jjaf167-B97","first-page":"478","article-title":"Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease","volume":"116","author":"Ramos Belinch\u00f3n","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"key":"2025102819145573800_jjaf167-B98","author":"Gold","year":"2025"},{"key":"2025102819145573800_jjaf167-B99","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.14309\/ajg.0000000000003208","article-title":"Safety and effectiveness of glucagon-like peptide-1 receptor agonists in inflammatory bowel disease","volume":"120","author":"Anderson","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2025102819145573800_jjaf167-B100","doi-asserted-by":"crossref","first-page":"S-591","DOI":"10.1016\/S0016-5085(24)01827-4","article-title":"Sa1950 impact of Glp1 agonists on inflammatory biomarkers in patients with inflammatory bowel disease","volume":"166","author":"Sehgal","year":"2024","journal-title":"Gastroenterology"},{"key":"2025102819145573800_jjaf167-B101","doi-asserted-by":"crossref","first-page":"e51\u2013e51","DOI":"10.1038\/nutd.2012.29","article-title":"Visceral and subcutaneous adipose tissue from lean women respond differently to lipopolysaccharide-induced alteration of inflammation and glyceroneogenesis","volume":"2","author":"Vatier","year":"2012","journal-title":"Nutr Diabetes"},{"key":"2025102819145573800_jjaf167-B102","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1111\/all.16295","article-title":"Subcutaneous adipose tissue: implications in dermatological diseases and beyond","volume":"79","author":"Ziadlou","year":"2024","journal-title":"Allergy"},{"key":"2025102819145573800_jjaf167-B103","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S2468-1253(22)00198-4","article-title":"Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial","volume":"7","author":"K\u00e5rhus","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102819145573800_jjaf167-B104","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/DCR.0b013e3182342ccb","article-title":"The impact of obesity on outcomes following major surgery for Crohn\u2019s disease: an American College of Surgeons National Surgical Quality Improvement Program assessment","volume":"54","author":"Causey","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"2025102819145573800_jjaf167-B105","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jamcollsurg.2013.01.053","article-title":"Does morbid obesity change outcomes after laparoscopic surgery for inflammatory bowel disease? Review of 626 consecutive cases","volume":"216","author":"Krane","year":"2013","journal-title":"J Am Coll Surg"},{"key":"2025102819145573800_jjaf167-B106","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3393\/jksc.2012.28.5.241","article-title":"Incidence and risk factors of parastomal hernia","volume":"28","author":"Sohn","year":"2012","journal-title":"J Korean Soc Coloproctol"},{"key":"2025102819145573800_jjaf167-B107","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","article-title":"Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study","volume":"67","author":"Kirchgesner","year":"2018","journal-title":"Gut"},{"key":"2025102819145573800_jjaf167-B108","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/acr.22892","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in cutaneous lupus erythematosus: a population-based cohort study","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025102819145573800_jjaf167-B109","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ajg.2011.63","article-title":"Inflammatory bowel disease is associated with an increased incidence of cardiovascular events","volume":"106","author":"Yarur","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2025102819145573800_jjaf167-B110","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/apt.16879","article-title":"Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"55","author":"Zamani","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819145573800_jjaf167-B111","doi-asserted-by":"crossref","first-page":"518","DOI":"10.21037\/hbsn-2021-13","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide","volume":"10","author":"Mantovani","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025102819145573800_jjaf167-B112","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr Nutr Rep"},{"key":"2025102819145573800_jjaf167-B113","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00595-016-1357-x","article-title":"Impact of sarcopenia on surgical site infection after restorative proctocolectomy for ulcerative colitis","volume":"47","author":"Fujikawa","year":"2017","journal-title":"Surg Today"},{"key":"2025102819145573800_jjaf167-B114","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00595-019-01893-8","article-title":"Sarcopenia as an independent predictor of the surgical outcomes of patients with inflammatory bowel disease: a meta-analysis","volume":"50","author":"Er\u0151s","year":"2020","journal-title":"Surg Today"},{"key":"2025102819145573800_jjaf167-B115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/ibd\/izy212","article-title":"Sarcopenia and inflammatory bowel disease: a systematic review","volume":"25","author":"Ryan","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819145573800_jjaf167-B116","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes Rev"},{"key":"2025102819145573800_jjaf167-B117","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"2025102819145573800_jjaf167-B118","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13679-023-00506-3","article-title":"GLP-1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and effective use","volume":"12","author":"Arvanitakis","year":"2023","journal-title":"Curr Obes Rep"},{"key":"2025102819145573800_jjaf167-B119","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1007\/s10620-024-08720-2","article-title":"Efficacy and safety of GLP-1 agonists on metabolic parameters in non-diabetic patients with inflammatory bowel disease","volume":"69","author":"St-Pierre","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2025102819145573800_jjaf167-B120","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025102819145573800_jjaf167-B121","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/advances\/nmac037","article-title":"Dietary interventions for gastroparesis: a systematic review","volume":"13","author":"Eseonu","year":"2022","journal-title":"Adv Nutr"},{"key":"2025102819145573800_jjaf167-B122","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/flgastro-2024-102995","article-title":"Anti-obesity drugs for the gastroenterologists","volume":"16","author":"Sharkey","year":"2025","journal-title":"Frontline Gastroenterol"},{"key":"2025102819145573800_jjaf167-B123","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/gutjnl-2023-329651","article-title":"Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study","volume":"73","author":"Liu","year":"2024","journal-title":"Gut"},{"key":"2025102819145573800_jjaf167-B124","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"2025102819145573800_jjaf167-B125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cpt.2430","article-title":"Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes","volume":"111","author":"Faillie","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025102819145573800_jjaf167-B126","doi-asserted-by":"crossref","first-page":"izae276","DOI":"10.1093\/ibd\/izae276","article-title":"Glucagon-like peptide 1 receptor agonists are not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease\u2014a Danish nationwide cohort study","volume":"31","author":"Nielsen","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819145573800_jjaf167-B127","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1345\/aph.1M676","article-title":"Association of pancreatitis with glucagon-like peptide-1 agonist use","volume":"44","author":"Anderson","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2025102819145573800_jjaf167-B128","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J Clin Med"},{"key":"2025102819145573800_jjaf167-B129","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025102819145573800_jjaf167-B130","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"2025102819145573800_jjaf167-B131","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"2025102819145573800_jjaf167-B132","doi-asserted-by":"crossref","first-page":"sfae250","DOI":"10.1093\/ckj\/sfae250","article-title":"Semaglutide-associated kidney injury","volume":"17","author":"Begum","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025102819145573800_jjaf167-B133","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2215\/CJN.0000000584","article-title":"The impact of glucagon-like peptide-1 receptor agonists on kidney outcomes: a meta-analysis of randomized placebo-controlled trials","volume":"20","author":"Mendon\u00e7a","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102819145573800_jjaf167-B134","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-022-00634-6","article-title":"Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment","volume":"19","author":"Bisgaard","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025102819145573800_jjaf167-B135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2036.2011.04915.x","article-title":"Co-morbid diabetes in patients with Crohn\u2019s disease predicts a greater need for surgical intervention","volume":"35","author":"Harper","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819145573800_jjaf167-B136","doi-asserted-by":"crossref","first-page":"24433","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci Rep"},{"key":"2025102819145573800_jjaf167-B137"},{"key":"2025102819145573800_jjaf167-B138","year":"2025"},{"key":"2025102819145573800_jjaf167-B139","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.japh.2023.10.037","article-title":"The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception","volume":"64","author":"Skelley","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2025102819145573800_jjaf167-B140","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025102819145573800_jjaf167-B141","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"2025102819145573800_jjaf167-B142","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med"},{"key":"2025102819145573800_jjaf167-B143","doi-asserted-by":"crossref","first-page":"e01544","DOI":"10.14309\/crj.0000000000001544","article-title":"Dramatic changes in thiopurine metabolite levels in a patient with inflammatory bowel disease treated with tirzepatide for weight loss","volume":"11","author":"Klein","year":"2024","journal-title":"ACG Case Rep J"},{"key":"2025102819145573800_jjaf167-B144","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s10620-024-08504-8","article-title":"Impact of obesity and metabolic syndrome on IBD outcomes","volume":"69","author":"Mahmoud","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2025102819145573800_jjaf167-B145","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ecco-jcc\/jjv084","article-title":"Body mass index and smoking affect thioguanine nucleotide levels in inflammatory bowel disease","volume":"9","author":"Poon","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2025102819145573800_jjaf167-B146","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.gie.2024.11.024","article-title":"Quality of bowel preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists","volume":"101","author":"Gala","year":"2025","journal-title":"Gastrointest Endosc"},{"key":"2025102819145573800_jjaf167-B147","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.gie.2024.07.014","article-title":"Glucagon-like peptide-1 receptor agonists and capsule endoscopy in patients with diabetes: a matched cohort study","volume":"101","author":"Odah","year":"2025","journal-title":"Gastrointest Endosc"},{"key":"2025102819145573800_jjaf167-B148","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cgh.2023.11.002","article-title":"AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication","volume":"22","author":"Hashash","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819145573800_jjaf167-B149","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12794","article-title":"Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease","volume":"40","author":"Gizard","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819145573800_jjaf167-B150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/ebmental-2020-300223","article-title":"Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study","volume":"24","author":"Irving","year":"2021","journal-title":"Evid Based Ment Health"},{"key":"2025102819145573800_jjaf167-B151","author":"Damas","year":"2025"},{"key":"2025102819145573800_jjaf167-B152"},{"key":"2025102819145573800_jjaf167-B153","author":"Eli Lilly and Company","year":"2025"},{"key":"2025102819145573800_jjaf167-B154","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ecco-jcc\/jjad073","article-title":"A mediterranean diet pattern improves intestinal inflammation concomitant with reshaping of the bacteriome in ulcerative colitis: a randomised controlled trial","volume":"17","author":"Haskey","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025102819145573800_jjaf167-B155"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf167\/64287685\/jjaf167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf167\/64287685\/jjaf167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf167\/64287685\/jjaf167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:15:18Z","timestamp":1761693318000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf167\/8256208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":155,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf167","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,9]]},"article-number":"jjaf167"}}